Susoctocog Alfa

證據等級: L5

預測適應症: 10 個

Susoctocog Alfa: From Acquired Hemophilia A to Primary Release Disorder of Platelets

One-Sentence Summary

Susoctocog alfa (recombinant B-domain-deleted porcine Factor VIII, marketed elsewhere as Obizur®) is used to control bleeding in acquired hemophilia A — a fact confirmed by the evidence pack's own literature even though the original_indications field is empty (data gap). TxGNN's top-ranked prediction, primary release disorder of platelets, has zero supporting clinical trials or publications, and the model's own mechanistic rationale flags it as biologically implausible. The only predictions in this pack that carry real clinical evidence (hemophilia; acquired coagulation factor deficiency) largely overlap with the drug's known original use rather than representing a genuinely novel indication.

Quick Overview

Item	Content
Original Indication	Acquired Hemophilia A (inferred from cited literature, e.g. PMID 27098420; `original_indications` field itself is empty — data gap)
Predicted New Indication (TxGNN rank #1)	Primary release disorder of platelets
TxGNN Prediction Score	99.94%
Evidence Level	L5 (model prediction only, no supporting studies)
Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available (original_moa: [Data Gap]). Based on the drug class and the evidence pack's own literature, susoctocog alfa is a recombinant porcine Factor VIII product that restores thrombin generation by directly replacing FVIII activity — used clinically to stop bleeding in patients with acquired hemophilia A (autoantibody-mediated FVIII inhibition).

TxGNN's #1-ranked prediction, primary release disorder of platelets, is a defect in platelet granule release, a mechanism entirely upstream of and independent from the coagulation-factor cascade that susoctocog alfa acts on. The evidence pack's own repurposing_rationale explicitly states this: the mechanistic link is weak, and the high score is likely driven by a "bleeding tendency" semantic cluster in the TxGNN knowledge graph rather than genuine biological relevance. The same pattern holds for ranks 2, 3, 6, 7, 8, 9, and 10 (pseudo-von Willebrand disease, Glanzmann thrombasthenia, Scott syndrome, collagen-receptor bleeding disorders, constitutional thrombocytopenia, congenital Factor XIII deficiency, and adenosine deaminase deficiency) — all are platelet-function, other-coagulation-factor, or entirely unrelated (immunodeficiency) disorders that FVIII replacement cannot mechanistically correct, and none have any clinical trial or literature support.

The only candidates with genuine mechanistic coherence and real-world evidence are hemophilia (rank 4) and acquired coagulation factor deficiency (rank 5) — but both are effectively restatements of the drug's known approved use for acquired hemophilia A, not novel repurposing opportunities. This suggests the evidence pack's original_indications field should have captured this indication, and its emptiness is a data-completeness issue rather than evidence that no original indication exists.

Clinical Trial Evidence (Rank #1: Primary release disorder of platelets)

Currently no related clinical trials registered.

Literature Evidence (Rank #1: Primary release disorder of platelets)

Currently no related literature available.

Supplementary: Full TxGNN Ranking Overview

Because this evidence pack evaluates multiple candidate indications, the full ranking is summarized below for transparency:

Rank	Predicted Indication	Score	Evidence Level	Recommendation	Note
1	Primary release disorder of platelets	99.94%	L5	Hold	No evidence; mechanistically weak
2	Pseudo-von Willebrand disease	99.93%	L5	Hold	No evidence; mechanistically weak
3	Glanzmann thrombasthenia	99.88%	L5	Hold	No evidence; mechanistically weak
4	Hemophilia	99.74%	L3	Proceed with Guardrails	1 PMS trial + 21 publications, but overlaps with known original indication
5	Acquired coagulation factor deficiency	99.64%	L3	Proceed with Guardrails	Multiple real-world/cohort studies, same overlap caveat
6	Scott syndrome	99.60%	L5	Hold	No evidence; mechanistically weak
7	Bleeding diathesis (collagen receptor defect)	99.17%	L5	Hold	No evidence; mechanistically weak
8	Hemorrhagic disorder (constitutional thrombocytopenia)	99.17%	L5	Hold	No evidence; mechanistically weak
9	Congenital Factor XIII deficiency	99.15%	L5	Hold	No evidence; different clotting-cascade step
10	Adenosine deaminase deficiency	99.04%	L5	Hold	Likely spurious; no biological relevance to coagulation

Best-Evidenced Candidate: Hemophilia (Rank 4)

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06461533	N/A	Recruiting	25	Japan post-marketing all-case surveillance of IV susoctocog alfa for acquired hemophilia A bleeding events; observational safety/effectiveness data collection

PMID	Year	Type	Journal	Key Findings
39158833	2024	Phase II/III open-label	Int J Hematol	Efficacy/safety of rpFVIII in Japanese AHA patients (NCT04580407)
37510704	2023	Case Series/Review	J Clin Med	Surgical prophylaxis with susoctocog-alfa in AHA
40812597	2025	PK Study	J Thromb Haemost	PK-guided dosing strategies for precise FVIII control
32698943	2020	Real-world Registry	Blood Transfus	9 elderly AHA patients, Italian multicentre real-world experience
27098420	2016	Review	Drugs	Comprehensive review, original pivotal Phase II/III trial (n=28) supporting approval

Market Information

Not marketed; no authorizations on record (total_licenses: 0, licenses: []).

Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA/label warnings and contraindications data is flagged as a Blocking data gap (DG001) in this evidence pack — this alone prevents a full safety (S1) evaluation regardless of efficacy evidence.

Conclusion and Next Steps

Decision: Hold

Rationale: The top TxGNN-ranked prediction (primary release disorder of platelets) has no clinical trial or literature support and is flagged by the model's own rationale as a likely knowledge-graph artifact. The only mechanistically sound, evidence-backed candidates (hemophilia, acquired coagulation factor deficiency) are not genuinely novel — they overlap with the drug's known original indication — so this pack does not currently support a new repurposing opportunity. A Blocking safety data gap (label warnings/contraindications) further precludes proceeding.

To proceed, the following is needed:

Resolve DG001: obtain TFDA/EMA label warnings, contraindications, and DDI data before any safety evaluation
Resolve DG002: obtain confirmed mechanism-of-action data from DrugBank
Correct the original_indications field to reflect the drug's actual approved use (acquired hemophilia A) so future TxGNN predictions are properly filtered against known indications
If a genuinely novel indication is desired, re-run prediction excluding hemophilia-adjacent disease clusters and require ≥L3 evidence before advancing to guardrail review
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.